Skip to main content

Raquel Hladun Alvaro

Institutions of which they are part

Predoctoral researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Raquel Hladun Alvaro

Institutions of which they are part

Predoctoral researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Projects

Nuevas estrategias de inhibición de la vía Hedgehog como dianas terapéuticas en el rabdominosarcoma.

IP: Josep Roma Castanyer
Collaborators: Josep Sánchez de Toledo Codina, Anna Llort Sales, Raquel Hladun Alvaro, Patricia Zarzosa Martinez
Funding agency: Instituto de Salud Carlos III
Funding: 87120
Reference: PI18/00398
Duration: 01/01/2019 - 31/12/2021

Investigació translacional en càncer infantil (GRE)

IP: Josep Sánchez de Toledo Codina
Collaborators: Aroa Soriano Fernández, Maria Cristina Díaz de Heredia Rubio, Miguel Segura Ginard, Anna Llort Sales, Raquel Hladun Alvaro, Laura Alonso Garcia, Josep Roma Castanyer
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 30000
Reference: 2014 SGR 660
Duration: 01/01/2014 - 31/12/2016

Phase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action (EUROFANCOLEN) Grant Agreement nº 305421

IP: Josep Sánchez de Toledo Codina
Collaborators: Jordi Barquinero Mañez, Maria Cristina Díaz de Heredia Rubio, Raquel Hladun Alvaro
Funding agency: EUROPEAN COMMISSION
Funding: 285000
Reference: EUROFANCOLEN_FP7HEALTH2012
Duration: 01/01/2013 - 31/12/2018

Ensayo clínico Fase I/II para evaluar la seguridad y eficacia de la movilización y colecta de células CD34+ tras tratamiento con plerixafor y filgrastim en pacientes con Anemia de Fanconi para su posterior uso en ensayos de terapia génica

IP: Maria Cristina Díaz de Heredia Rubio
Collaborators: Josep Sánchez de Toledo Codina, Raquel Hladun Alvaro
Funding agency: Ministerio Sanidad
Funding: 437580
Reference: EC11-559
Duration: 01/01/2012 - 30/06/2018

Related news

The study analyzes the impact of COVID-19 on people with rare red blood cell disorders, identifying risk factors for severe forms of the disease.

The association, once again, has shown its commitment to oncological research with a donation of €19,197 to the Cancer and Hematological Diseases Group for Children at VHIR.

The prestigious journal The Lancet has published the results of this study, which is the result of more than 20 years of pre-clinical research and 7 years of patient follow-up.

Related professionals

Rosa Maria Gracia Gozalo

Rosa Maria Gracia Gozalo

Shock, Organ Dysfunction and Resuscitation
Read more
Cristina Padros Fornieles

Cristina Padros Fornieles

Research technician
Hepato-bilio-pancreatic surgery (HBP) and liver transplantation
Read more
Francisco Vidal Pérez

Francisco Vidal Pérez

Main researcher
Transfusional Medicine
Read more
Jorge Fernandez Engroba

Jorge Fernandez Engroba

Predoctoral researcher
Ophtalmology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.